Allergan Aesthetics Receives Positive CHMP Opinion for Boey, a Novel Neurotoxin

What happened

On May 21, 2026, AbbVie announced that the European Medicines Agency's CHMP adopted a positive opinion recommending approval of Boey (trenibotulinumtoxinE) for temporary improvement of moderate to severe glabellar lines in adults, with potential to be the first and only botulinum neurotoxin serotype E for aesthetic use. The opinion is based on Phase 3 data showing rapid onset (as early as 8 hours) and a duration of 2-3 weeks, offering a differentiated profile from existing toxins. This is a positive regulatory milestone for AbbVie's aesthetics segment, which has been pressured (FY2025 aesthetics down 6.1% to $4.86B). However, final European Commission approval is still pending, and commercial uptake will depend on physician adoption and payer coverage. The news does not alter the core investment thesis, which hinges on immunology execution (Skyrizi/Rinvoq) and Rinvoq exclusivity duration.

Implication

If approved and successfully launched, Boey could help stabilize aesthetics revenue and support the $5.0B 2026 guide, reducing a key overhang. However, the segment remains a secondary driver vs. immunology, and investors should monitor whether this offsets Juvederm's ongoing declines.

Thesis delta

No major shift: the positive CHMP opinion is a checkpoint in the aesthetics recovery narrative but does not change the WAIT rating. The bull case probability (20%) could increase if Boey drives tangible aesthetics growth, but near-term focus remains on immunology execution and Rinvoq exclusivity conditions.